Semaglutide is the active ingredient found in the brand-name medications Wegovy® and Ozempic®. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist prescribed as an adjunct to a healthy diet and exercise regimen for weight loss and management.

While every individual responds differently to medications, a medical study of 1961 participants demonstrated that in a 68-week period, participants lost an average body weight of ~15%. Furthermore, 1 out of 3 participants lost more than 20% of their baseline body weight.

Adults with a BMI of 30 or more (obesity category).

Adults with a BMI of 27-29 (overweight category), who also have at least one weight-related comorbid condition such as hypertension, diabetes type 2, or hyperlipidedemia.

Pediatrics, 12 years and older with a BMI in the 95th percentile or greater.

Semaglutide can be administered weekly, at any time of day but on the same day each week, with or without meals.

Semaglutide should be injected subcutaneously into upper arms, abdomen or thighs.

If there is a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MENS2) or in case of hypersensitivity to Semaglutide.

The most common side effects of Semaglutide include nausea, diarrhea/constipation, feeling bloated, heartburn, belching, dizziness, vomiting, and upset stomach.

Unfortunately, we are not accepting insurance for the weight loss program at this time.

We do accept FSA & HSA.

Semaglutide is dispensed by our contracted pharmacy. Current delivery time is 5-7 business days approximately.

Tirzepatide is the active ingredient found in the brand-name medications Mounjaro™ and Zepbound™. Tirzepatide combines a glucagon-like peptide-1 (GLP-1) receptor agonist and a glucose-dependent insulinotropic polypeptide (GIP) receptor, both of which are found in areas of the brain that regulate appetite.

While every individual responds differently to medications, a medical study of 783 participants demonstrated that in a 88-week period, participants lost an average body weight of ~26.6%.

Adults with a BMI of 30 or more (obesity category).

Adults with a BMI of 27-29 (overweight category), who also have at least one weight-related comorbid condition such as hypertension, diabetes type 2, or hyperlipidedemia.

Tirzepatide can be administered weekly, at any time of day but on the same day each week, with or without meals.

Tirzepatide should be injected subcutaneously into upper arms, abdomen or thighs.

If there is a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MENS2) or in case of hypersensitivity to Tirzepatide.

The most common side effects of Tirzepatide include nausea, diarrhea/constipation, feeling bloated, heartburn, belching, dizziness, vomiting, and upset stomach.

Unfortunately, we are not accepting insurance for the weight loss program at this time.

We do accept FSA & HSA.

Tirzepatide is dispensed by our contracted pharmacy. Current delivery time is 5-7 business days approximately.